CD19 and leukemia: To determine whether CD19@NP/17-DMAG and imatinib could reverse this exhausted T cell phenotype in BCR-ABL1+ B-ALL, we administered the indicated treatments beginning on day 8 post-leukemia cell injection (Figure 4A).